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THERE is now substantial evidence from experiments involving the transplanta-
tion of primary or early transplant generation tumours in inbred strains, of the
antigenicity of chemically-induced tumours (Foley, 1953b; Prehn and Main,
1957; Klein et al., 1960; Old et al., 1962) and of virus-induced tumours (Habel,
1961 ; Sjogren et al., 1961 ; Klein et al., 1962). Using similar techniques, many
workers could find no evidence of immunity to spontaneous tumours (Foley,
1953a; Prehn and Main, 1957; Revesz, 1960) although others have reported
immunity to a number ofspontaneous mammary tumours (Morton, 1962; Riggins
and Pilch, 1964; Weiss et al., 1964). Data on the antigenicity of spontaneous
tumours, however, is still scarce. This report describes an investigation into the
antigenicity of a number of primary and early transplant generation carcinogen-
induced and spontaneous tumours in syngeneic, inbred mice.
MATERIALS AND METHODS
The inbred C57 (RCH) and Strong A strains of mice of the Leeds laboratory
stock were used. They were allowed food and water ad libitum.
The tumours used were sarcomas induced by the subcutaneous injection of
20-methylcholanthrene (MC) in C57 (RCH) male mice; a mammary carcinoma
induced by period gastric instillation and subcutaneous injection ofMC in Strong A
female mice, and spontaneous mammary carcinomas arising in old Strong A female
breeding mice. Tumours were used in their primary or early transplant genera-
tion, and recipient mice were of the same strain and sex as the tumour donor.
Tumours were excised aseptically and non-necrotic regions of the tumour chosen
for transplantation into the flank of recipient mice. Recipient mice received
either a small piece of tumour implant or 0-05 ml. of a coarse tumour cell suspen-
sion in Ringer's solution containing 100 I.U. of penicillin and 100 ,ug. of strepto-
mycin per ml. One to three weeks later, depending upon the tumour, when the
implants had grown to approximately 5 mm. in diameter, they were excised and
pooled to prepare a challenge tumour cell suspension for subcutaneous injection
into the opposite flank of " tumour sensitised " and control animals. Cell sus-
pensions were prepared in Ringer's solution containing penicillin and streptomycin,
by gentle trituration in a loose fitting glass homogeniser, followed by filtration
through a stainless steel mesh. The filtrate contained a high percentage of
isolated cells which were counted using a haemacytometer and testing with
0.050 % Trypan blue gave 40-60% unstained cells for the various tumours used.
Lymph node and spleen cell suspensions prepared in a similar manner gave
60-80% unstained cells with Trypan blue testing.H. J. SMITH
Preliminary experiments showed that 105 tumour cells in 01 ml. Ringer's
solutionwere generallyneededto give ahighincidenceofsuccessfulgrafts, and mice
injected with tumour were examined and palpated twice weekly to determine the
time of appearance of a nodule (designated a " take "). In these experiments all
nodules showed progressive growth and histological examination confirmed that
they were of donor tumour cell-type.
RESULTS
Antigenicity of MC-induced sarcomas in C57 (RCH) mice
Mice were implanted with a first transplant generation MC-induced sarcoma
which was later excised, whilst control mice received implants of normal muscle
tissue obtained from the tumour donor that were later excised, or were subjected
to sham operation. All the mice were later challenged with a tumour inoculum
prepared either from the same tumour as that used for sensitisation, or from a
tumour different from that used for sensitisation (Table I). The results show that
immunity could be achieved to MC-induced sarcomas, which was specific to the
same tumour used for sensitisation and challenge, with no cross-reactivity with a
number ofother MC-induced sarcomas tested.
TABLE I.-Antigenicity ofMC-Induced Sarcomas in Syngeneic C57 (RCH) Mice
No. takes/
Experiments Groups No. mice
(1) Sensitisedwith MC- . Tumoursensitised . 3/6a
induced sareoma and Controls 10/10
challenge withthe same
tumour
(2) Sensitised with MC- . Tumour sensitised . 0/6
induced sarcoma and Controls (muscle implants) 10/10
challenge withthe same
tumour
(3) Sensitised with various . Tumour sensitised . 2/10
MC-induced sarcomas Groups ofmice sensi- 2/3 )
andchallenge with tised to other MC- 6/6
one tumour induced sarcomas 5/5 L34/37
8/8
2/2
11/13J
Controls . 10/10
a - regrowth of sensitising tumour in mice accepting challenge tumour inoculum.
There were 5/22 takes in mice sensitised to tumours used for challenge, 34/37 takes in mice sensi-
tised to other MC-induced sarcomas, and 30/30 takes in controlmice. Comparison ofthe probabilities
using X2, ofthe experiments showing that sensitisation with MC-induced sareoma resulted in immunity
to challenge with the same tumour compared to control animals, gives a final P value_ < 0 001.
To determine if immunity could be demonstrated in the autologous hosts to
their own primary tumours, primaryMC-inducedtumours were excised and used to
prepare a cell suspension for injection into the original host and isologous control
mice (Table II). It proved difficult to excise the tumour completely, or to prepare
the optimum dosage oftumour cells for challenge in every case and in two experi-
ments the tumours did not take in any mice; in three experiments the tumour
took in all the mice and in three experiments the tumours took in control mice but
not in the original hosts.
832ANTIGENICITY OF MOUSE TUMOURS
TABLE II.-Antigenicity ofMC-Induced Primary Sarcomas in C57 (RCH) Mice
No. takes/
No. mice
Experiments showing no Autologous hosts . 0/2
takes in autologous and in Isologous hosts 0/10
isologous mice
Experiments showing takes . Autologous hosts 3/3a
in autologous and in Isologous hosts 15/15
isologous mice
Experiments showing no Autologous hosts . 0/3
takes in autologous mice but Isologous hosts 15/15
takes in isologous mice
a regrowth of primary tumour in three mice that also accepted the challenge tumour inoculum.
Antigenicity of MC-induced mammary tumoour in Strong A mice
Mice were implanted with a MC-induced mammary tumour which was later
excised and used to prepare a tumour inoculum of 105 cells for injection into
sensitised and control mice. There were no takes in the tumour sensitised group
and they were rechallenged with 106 tumour cells prepared from the same tumour
maintained in isologous mice. The results show that immunity could be attained
against an MC-induced mammary tumour in syngeneic mice (Table III).
TABLE III. Antigenicity of a MC-Induced Mammary Carcinoma in Strong A Mice
Dosage of No. takes/
Groups tumour cells No. mice
(1) Tumour sensitised 105 . 0/10
Controls 105 4/10
(2) Tumour sensitised
2nd challenge 106 . 2/9
Controls 106 8/10
Comparing tumour sensitised mice receiving 106 tumour cells to its respective control group
P-< 0 05.
Antigenicity of spontaneous mnammary tumours in Strong A mice
The results of this series of experiments are presented in Table IV.
Mice were sensitised with a first transplant generation tumour which was later
excised and used to prepare a challenge tumour inoculum for injection into
sensitised and control mice (Experiment 1). The experiment was repeated using
a primary tumour, a portion of which was used for implantation followed by
excision. The tumour donor was now killed and a tumour cell suspension and a
spleen cell suspension were prepared. The " tumour sensitised " mice and
control mice received 105 tumour cells and a third group of mice received 105
tumour cells mixed with 107 spleen cells (Experiment 2). No evidence of tumour
immunity could be seen in these experiments.
The effect of mixing tumour cells with lymphoid cells of the axillary, brachial
and inguinal lymph nodes and spleens from mice that had been sensitised with a
low dosage of tumour cells insufficient to give takes, was also tried. It was
observed that mixing of 105 tumour cells with 107 or 105 lymphoid cells from such
" tumour sensitised " mice had an inhibitory effect upon tumour take compared
to mice receiving tumour cells only (Experiment 3). However, as lymphoid cells
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from untreated mice were also found to have an inhibitory effect upon tumour
take, the inhibition observed with lymphoid cells from "tumour sensitised " mice
also appears to be the expression of this innate resistance to tumour transplanta-
tion (Experiment 4). The experiment was repeated using tumour cells obtained
from a primary tumour mixed with spleen cells from untreated mice or with spleen
cells of the tumour donor, and implanting into isologous mice (Experiment 5).
The results show that lymphoid cells from untreated mice had an inhibitory effect
upon tumour take whilst lymphoid cells from the primary tumour bearing hosts
were ineffective.
DISCUSSION
Foley (1953b) reported that ligation of MC-induced sarcoma implants in mice
rendered the hosts resistant to further challenge with the same tumour, and there
have been many subsequent publications substantiating this finding (Prehn and
Main, 1957; Klein et al., 1960; Revesz, 1960; Old et al., 1962). Similarly, in the
experiments reported here, it was observed that implantation of MC-induced
sarcoma, followed by excision, rendered the host resistant to challenge with the
same tumour but not to other syngeneic MC-induced sarcomas. A lack of cross-
reactivity between different MC-induced sarcomas has been noted by others
(Klein et al., 1960; Prehn, 1962; Old et al., 1962). The failure ofnormal muscle
implants from the tumour donor or of other MC-induced sarcoma implants to
immunise the host, indicates that this is a true tumour specific immunity. The
autochthonous host too has been shown to be capable of reacting against its
primary tumour. Klein et al. (1960) demonstrated that removal of primary
MC-induced sarcoma rendered the hosts resistant to challenge with the same
tumour and, in the experiments described here, it was found that a few mice
whose primary MC-induced tumour was completely excised, resisted the challenge
tumour inoculum whilst control mice accepted the tumour grafts. It was noted
that some " sensitised " mice, showing regrowth of the sensitising tumour at site
of excision, accepted the challenge tumour inoculum, indicating that an immune
reaction may occur in the sensitised host but be too weak to be effective against
an excess oftumour cells. Ifthe number ofcells is reduced (e.g. complete extirpa-
tion of the sensitising tumour) then the immune reaction may effectively resist
challenge with a low dosage of tumour cells. Analogous results have been
reported by Mikulska et al. (1964) working with 3,4-benzopyrene-induced sarcomas
in the rat.
Prehn (1960) has demonstrated tumour immunity to MC-induced mammary
tumours in mice and this was confirmed in an experiment where tumour immunity
to a MC-induced mammary tumour in sensitised syngeneic Strong A mice was
achieved. Using similar methods in the same strain of mice, however, immunity
to spontaneous Strong A mammary tumours could not be demonstrated and this
result is similar to that found by many workers who were able to achieve immunity
to carcinogen-induced tumours but not to spontaneous tumours (Foley, 1953a;
Prehn and Main, 1957; Revesz, 1960), although others have reported some
degree of successful immunisation against spontaneous mammary tumours
(Morton, 1962; Riggins and Pilch, 1964; Martin et al., 1964; Weiss et al., 1964).
As a possibly more sensitive technique for detecting tumour immunity, the
effect ofmixing oftumour cells with lymphoid cells from tumour sensitised donors
and implanting into isologous mice was also investigated. Woodruff and Symes
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(1962) suggested that splenomegaly in Strong A mice with spontaneous mammary
tumour was an expression of immune reactivity against tumour antigens.
Woodruff (1963) observed that mixing of 106 cells from a Strong A tumour with
4 X 104 spleen cells from the tumour donor had an inhibitory effect upon tumour
growth when injected intraperitoneally into isologous mice, but when the dosage
of spleen cells was increased the inhibitory effect was lost. Mackay (1965) found
that mixing ofStrong A tumour cells with spleen cells ofsyngeneic tumour bearing
mice and implanting subcutaneously in isologous mice had no effect on tumour
growth. In the experiments reported here, mixing of tumour cells of a primary
mammary carcinoma with spleen cells from the same host was without effect upon
tumour takes in isologous mice. When lymphoid cells from syngeneic " tumour
sensitised " mice were used, there was some delay in tumour takes compared to
mice receiving tumour cells only, but, in view of the unexpected finding that
lymphoid cells of untreated mice also had an inhibitory effect, this phenomenon
appears to be an expression of defence mechanisms to tumour growth present in
normal mice. The existence of inhibitory factors in untreated hosts to tumour
transplants is also indicated by the observation that mixing of a large number of
X-irradiated mammary cancer cells enhanced the take of a small viable inoculum
of the tumour in isologous mice (Revesz, 1956; Wallace, 1965), possibly by
swamping host defence mechanisms. Axelrad and Van der Gaag (1959), using
cell suspensions prepared from excised primary mammary tumours, found that
tumours took at lower cell dosages in autologous hosts than in isologous hosts,
indicating that isologous mice possessed some degree of resistance which the
autologous host lacked.
The resistance of untreated mice to spontaneous tumour transplants may be
related to the presence ofthe mammary tumour virus (MTV) in the strains ofmice
used. It has been shown for a number oftumour-inducing viruses that immunisa-
tion of adult mice with the virus would result in immunity to later challenge with
tumours induced by that virus (Habel, 1962; Klein et al., 1958; Sjogren, 1960).
Lavrin et al. (1966) reported that transplantation of MTV+ hyperplastic alveolar
nodules ofthe mammary gland into syngeneic adult MTV free hosts renders them
resistant to later challenge with MTV+ mammary carcinoma. Neonatal infection
of mice with MTV, however, renders them " tolerant " to later challenge with
MTV+ mammary carcinoma compared to control MTV free mice (Morton, 1964;
Lavrin et al., 1966). In contrast, when immune reactivity wholly within an MTV+
strain is considered, it is clear from the experimentsindicating host resistanceto the
transplantation ofspontaneous mammary tumours that infection ofneonatal mice
with MTV does not render them tolerant to later challenge with tumour, butrather
an immune response is engendered, which is expressed in adult animals but is
absent from primary tumour-bearing hosts. Indeed, Blair et al. (1966) demon-
strated antibodies against MTV in adult mice that had been neonatally injected
with MTV, but MTV-injected mice which spontaneously developed mammary
tumours did not produce detectable antibody titres against MTV. This is of
interest in view of the results reported here that lymphoid cells from isologous
untreated mice had an inhibitory effect upon tumour takes, whilst lymphoid cells
from mice bearing primary mammary tumours were ineffective.
The lack of immune reactivity in hosts bearing primary tumours may be due
to " exhaustion " ofthe immune response by an excess of MTV tumour antigens,
or it is possible that the host immunity to MTV suppresses MTV tumour formation
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and abrogation of this immune reaction in some manner (e.g. pllysiological
changes during ageing) allows the development of MTV tumours. It will be of
interest to determine ifeither ofthese explanations is correct.
SUMMARY
Immunity to MC-induced sarcomas could be demonstrated in mice receiving a
tumour transplant which was later excised, upon challenge with the same tumour.
Immunity was specific to the particular MC-induced sarcoma used for sensitisation
and for challenge, with no cross-reactivity with other syngeneic MC-induced
sarcomas. The tumour takes in " sensitised " mice also showing regrowth of the
sensitising tumour indicates that there is a critical level of host immunity to
MC-induced sarcomas which is masked if an excess of tumour cells is present.
Using similar techniques, it was possible to demonstrate tumour immunity to a
MC-induced mammary tumour but not to spontaneous mammary tumours.
Mixing oftumour cells with spleen cells from the primary host and implanting
into isologous mice was also ineffective, but mixing oftumour cells with lymphoid
cells from " tumour sensitised " or untreated mice and implanting in isologous
mice had an inhibitory effect upon tumour takes. The possibility that the innate
host resistance to " spontaneous " tumour transplants is associated with the
presence of MTV in the strain of mice used was discussed.
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